

WEST

Help

Logout

Interrupt

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Preferences

Cases

Search Results -

Terms	Documents
von willebrand complex and L8	178035

Database:

US Patents Full-Text Database	▲
US Pre-Grant Publication Full-Text Database	
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	
IBM Technical Disclosure Bulletins	▼

Search:

L9

Refine Search

Recall Text

Clear

Search History
DATE: Friday, December 05, 2003 [Printable Copy](#) [Create Case](#)
Set Name Query
 side by side

Hit Count Set Name
 result set
DB=USPT; PLUR=YES; OP=OR

<u>L9</u>	von willebrand complex and L8	178035	<u>L9</u>
<u>L8</u>	l3 and cation exchange chromatography	396590	<u>L8</u>
<u>L7</u>	preparation and L6	46853	<u>L7</u>
<u>L6</u>	virus safe and L5	66535	<u>L6</u>
<u>L5</u>	l3 and L4	148883	<u>L5</u>
<u>L4</u>	cation exchange	301373	<u>L4</u>
<u>L3</u>	factor VIII adj2 von Willebrand factor complex	939911	<u>L3</u>
<u>L2</u>	6605222.pn.	1	<u>L2</u>
<u>L1</u>	6228613.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPAFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 16 NOV 24 MSDS-CCOHS file reloaded

NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:35:15 ON 05 DEC 2003

=> file medline, uspatful, dgene, embase, wpids, fsta, biosis,		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'MEDLINE' ENTERED AT 11:37:05 ON 05 DEC 2003

FILE 'USPATFULL' ENTERED AT 11:37:05 ON 05 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 11:37:05 ON 05 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 11:37:05 ON 05 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 11:37:05 ON 05 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 11:37:05 ON 05 DEC 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'BIOSIS' ENTERED AT 11:37:05 ON 05 DEC 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

=> s factor VIII and von Willebrand factor complex
L1 150 FACTOR VIII AND VON WILLEBRAND FACTOR COMPLEX

=> s factor VIII/vWF-complex
'VWF-COMPLEX' IS NOT A VALID FIELD CODE
'VWF-COMPLEX' IS NOT A VALID FIELD CODE
'VWF-COMPLEX' IS NOT A VALID FIELD CODE
'VWF-COMPLEX' IS NOT A VALID FIELD CODE
'VWF-COMPLEX' IS NOT A VALID FIELD CODE
'VWF-COMPLEX' IS NOT A VALID FIELD CODE
'VWF-COMPLEX' IS NOT A VALID FIELD CODE
L2 0 FACTOR VIII/VWF-COMPLEX

=> s factor VIII ()von Willibrand Factor () complex
L3 0 FACTOR VIII (W) VON WILLIBRAND FACTOR (W) COMPLEX

=> s l1 and cation exchange chromatography
L4 1 L1 AND CATION EXCHANGE CHROMATOGRAPHY

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 1 USPATFULL on STN
TI Method for producing a **factor VIII/von Willebrand factor complex**
AB The invention relates to a method for the production of **factor VIII:C/von Willebrand factor complex** from plasma or a plasma fraction by chromatography in a cation exchanger, wherein the **factor VIII:C/von Willebrand factor complex** is obtained with at least 300 times the purity of the plasma and the yield of **factor VIII:C** and the von Willebrand factor is at least 50% in relation to cryoprecipitates or analogous plasma fractions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:215997 USPATFULL

TITLE: Method for producing a **factor VIII/von Willebrand factor complex**

INVENTOR(S): Linnau, Yendra, Vienna, AUSTRIA

Schoenhofer, Wolfgang, St. Poelten, AUSTRIA

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6605222 B1 20030812
 WO 9943712 19990902
 APPLICATION INFO.: US 2001-623245 20010319 (9)
 WO 1999-AT48 19990225

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1998-866	19980520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Therkorn, Ernest G.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP, Fedrick, Michael F.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	203	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 11:35:15 ON 05 DEC 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 11:37:05 ON 05 DEC 2003

L1 150 S FACTOR VIII AND VON WILLEBRAND FACTOR COMPLEX
 L2 0 S FACTOR VIII/VWF-COMPLEX
 L3 0 S FACTOR VIII () VON WILLIBRAND FACTOR () COMPLEX
 L4 1 S L1 AND CATION EXCHANGE CHROMATOGRAPHY

=> s low molecular weight vWF multimer
 L5 0 LOW MOLECULAR WEIGHT VWF MULTIMER

=> s l1 and virus-safe
 L6 1 L1 AND VIRUS-SAFE

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 1 USPATFULL on STN
 TI Stable **factor VIII/von Willebrand factor complex**
 AB There are disclosed a stable **factor VIII** /vWF-complex, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:67424 USPATFULL
 TITLE: Stable **factor VIII/von Willebrand factor complex**
 INVENTOR(S): Fischer, Bernhard, Vienna, Austria
 Mitterer, Artur, Mannsdorf, Austria
 Dorner, Friedrich, Vienna, Austria
 Eibl, Johann, Vienna, Austria
 PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228613	B1	20010508
	WO 9734930		19970925
APPLICATION INFO.:	US 1998-142768		19981106 (9)
	WO 1997-AT55		19970313
			19981106 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-494	19960315
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Robinson, Hope A.	
LEGAL REPRESENTATIVE:	Heller Ehrman White & McAuliffe	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)	
LINE COUNT:	1098	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 11:35:15 ON 05 DEC 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 11:37:05 ON 05 DEC 2003

L1 150 S FACTOR VIII AND VON WILLEBRAND FACTOR COMPLEX
 L2 0 S FACTOR VIII/VWF-COMPLEX
 L3 0 S FACTOR VIII () VON WILLIBRAND FACTOR () COMPLEX
 L4 1 S L1 AND CATION EXCHANGE CHROMATOGRAPHY
 L5 0 S LOW MOLECULAR WEIGHT VWF MULTIMER
 L6 1 S L1 AND VIRUS-SAFE

=> s l1 and preparation

L7 33 L1 AND PREPARATION

=> s l7 and cation exchange chromatography

L8 1 L7 AND CATION EXCHANGE CHROMATOGRAPHY

=> d l8 ti abs ibib tot

L8 ANSWER 1 OF 1 USPATFULL on STN

TI Method for producing a **factor VIII/von Willebrand factor complex**

AB The invention relates to a method for the production of **factor VIII:C/von Willebrand factor complex** from plasma or a plasma fraction by chromatography in a cation exchanger, wherein the **factor VIII:C/von Willebrand factor complex** is obtained with at least 300 times the purity of the plasma and the yield of **factor VIII:C** and the von Willebrand factor is at least 50% in relation to cryoprecipitates or analogous plasma fractions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:215997 USPATFULL

TITLE: Method for producing a **factor VIII/von Willebrand factor complex**

INVENTOR(S): Linnau, Yendra, Vienna, AUSTRIA

Schoenhofer, Wolfgang, St. Poelten, AUSTRIA

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6605222	B1	20030812
	WO 9943712		19990902

has date

APPLICATION INFO.: US 2001-623245 20010319 (9)
WO 1999-AT48 19990225

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1998-866	19980520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Therkorn, Ernest G.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP, Fedrick, Michael F.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	203	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 11:35:15 ON 05 DEC 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 11:37:05 ON 05 DEC 2003

L1 150 S FACTOR VIII AND VON WILLEBRAND FACTOR COMPLEX
L2 0 S FACTOR VIII/VWF-COMPLEX
L3 0 S FACTOR VIII ()VON WILLIBRAND FACTOR () COMPLEX
L4 1 S L1 AND CATION EXCHANGE CHROMATOGRAPHY
L5 0 S LOW MOLECULAR WEIGHT VWF MULTIMER
L6 1 S L1 AND VIRUS-SAFE
L7 33 S L1 AND PREPARATION
L8 1 S L7 AND CATION EXCHANGE CHROMATOGRAPHY

=> d l7 ti abs ibib 1-5

L7 ANSWER 1 OF 33 MEDLINE on STN

TI Isolation of the **factor VIII-von Willebrand factor complex** directly from plasma by gel filtration.

AB A high capacity gel filtration system was developed with the purpose of isolating **factor VIII** (FVIII) and von Willebrand factor (vWF) directly from plasma in significantly higher yields than obtained by cryoprecipitation, the technique most commonly used to recover FVIII-vWF from human plasma. After laboratory-scale gel filtration of plasma, a FVIII-containing fraction was collected containing about 90% of FVIII in the applied plasma and with almost tenfold higher purity than that obtained by cryoprecipitation. The gel filtration step has been scaled up for use as the initial step in the manufacturing process for a FVIII **preparation** (Nordiate).

ACCESSION NUMBER: 1999007008 MEDLINE

DOCUMENT NUMBER: 99007008 PubMed ID: 9792522

TITLE: Isolation of the **factor VIII-von Willebrand factor complex** directly from plasma by gel filtration.

AUTHOR: Kaersgaard P; Barington K A

CORPORATE SOURCE: HemaSure Denmark A/S, Gentofte.

SOURCE: JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS, (1998 Sep 18) 715 (2) 357-67.
Journal code: 9714109. ISSN: 1387-2273.

PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199812

ENTRY DATE: Entered STN: 19990115

hand date

Last Updated on STN: 19990115
Entered Medline: 19981218

L7 ANSWER 2 OF 33 MEDLINE on STN

TI Concentrated DDAVP: further improvement in the management of mild **factor VIII** deficiencies.

AB This study was carried out to evaluate the pharmacological efficacy of a new concentrated 1 Deamino - (8-D-arginine)-vasopressin (DDAVP) **preparation**. Concentrated DDAVP (C-DDAVP), (40 micrograms/mL) was given subcutaneously (s.c.) in hemophilia and von Willebrand Disease (vWD), and the response was evaluated in terms of **factor VIII/vWF (VIII/von Willebrand Factor)** **complex** response. This response was also compared to that obtained using the currently available commercial **preparation** (4 micrograms/mL) given either s.c. or intravenously (i.v.). The maximal f. VIII response after s.c. C-DDAVP was reached one hour after the injection (means: 3.5 times the resting values) with an average decline of 15% at two hours. The response to s.c. C-DDAVP in patients with hemophilia was slightly better than that obtained with the diluted brand, but the difference did not reach any statistical significance even when the schedules were compared in the same patients. In type I (platelet normal subtype) vWD, a higher response in terms of **factor VIII** :C increase in comparison with hemophiliacs was obtained. Both Ristocetin co-factor activity (RiCof) and bleeding time responded to this vasopressin analogue, when administered subcutaneously.

ACCESSION NUMBER: 88127637 MEDLINE
DOCUMENT NUMBER: 88127637 PubMed ID: 3124287
TITLE: Concentrated DDAVP: further improvement in the management of mild **factor VIII** deficiencies.
AUTHOR: Ghirardini A; Mariani G; Iacopino G; Tirindelli M C; Solinas S; Moretti T
CORPORATE SOURCE: Department of Human Biopathology, Hematology, University of Roma, La Sapienza, Italy.
SOURCE: THROMBOSIS AND HAEMOSTASIS, (1987 Oct 28) 58 (3) 896-8.
Journal code: 7608063. ISSN: 0340-6245.
PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198803
ENTRY DATE: Entered STN: 19900308
Last Updated on STN: 19990129
Entered Medline: 19880316

L7 ANSWER 3 OF 33 MEDLINE on STN

TI Effect of phospholipid on **factor VIII** coagulant activity and coagulant antigen.

AB Incubation of purified **factor VIII/von Willebrand factor complex** or plasma with certain phospholipid **preparation** induced a two to threefold increase in apparent **factor VIII** activity, while a slight decrease of **factor VIII** coagulant antigen was observed. Between six or eightfold activity increases occurred when 10-3 units/ml of thrombin was present during the incubation. When the phospholipid was added first and the thrombin added 30 minutes later a twofold increase in apparent **factor VIII** activity occurred during the first part and this activity was then increased threefold further after the addition of thrombin. In separate experiments using gel filtration on Sepharose 2B, association of **factor VIII** activity to phospholipid vesicles could be demonstrated. This phospholipid bound **factor VIII** could be activated by thrombin. The relationship between these observations and the formation of factor X activating complex is discussed.

ACCESSION NUMBER: 83303023 MEDLINE

DOCUMENT NUMBER: 83303023 PubMed ID: 6412394
 TITLE: Effect of phospholipid on **factor VIII**
 coagulant activity and coagulant antigen.
 AUTHOR: Broden K; Brown J E; Carton C; Andersson L O
 SOURCE: THROMBOSIS RESEARCH, (1983 Jun 15) 30 (6) 651-60.
 Journal code: 0326377. ISSN: 0049-3848.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198310
 ENTRY DATE: Entered STN: 19900319
 Last Updated on STN: 19900319
 Entered Medline: 19831028

L7 ANSWER 4 OF 33 USPATFULL on STN

TI Method and pharmaceutical composition for preventing and/or treating
 systemic inflammatory response syndrome
 AB A partial inhibitor of **factor VIII** such as a
 monoclonal antibody is useful for preventing and/or treating a disease
 selected from the group consisting of systemic inflammatory response
 syndrome, sepsis, septic shock, thrombus formation in the
 micro-vasculature and disseminated intravascular coagulation in a mammal
 by partially inhibiting thrombin formation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:250483 USPATFULL
 TITLE: Method and pharmaceutical composition for preventing
 and/or treating systemic inflammatory response syndrome
 INVENTOR(S): Saint-Remy, Jean-Marie R., Grez-Doiceau, BELGIUM
 Jacquemin, Marc G., Sart-Bernard, BELGIUM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175268	A1	20030918
APPLICATION INFO.:	US 2002-44569	A1	20020111 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Lee, Mann, Smith, McWilliams, Sweeney, & Ohlson, P.O. Box 2786, Chicago, IL, 60690-2786		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Page(s)		
LINE COUNT:	1430		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 33 USPATFULL on STN

TI Method for producing a **factor VIII/von**
Willebrand factor complex
 AB The invention relates to a method for the production of **factor**
VIII:C/von Willebrand factor
complex from plasma or a plasma fraction by chromatography in a
 cation exchanger, wherein the **factor VIII:C/**
von Willebrand factor complex is
 obtained with at least 300 times the purity of the plasma and the yield
 of **factor VIII:C** and the von Willebrand factor is at
 least 50% in relation to cryoprecipitates or analogous plasma fractions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:215997 USPATFULL
 TITLE: Method for producing a **factor VIII/**
von Willebrand factor
complex
 INVENTOR(S): Linnau, Yendra, Vienna, AUSTRIA

PATENT ASSIGNEE(S): Schoenhofer, Wolfgang, St. Poelten, AUSTRIA
Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6605222	B1	20030812
	WO 9943712		19990902
APPLICATION INFO.:	US 2001-623245		20010319 (9)
	WO 1999-AT48		19990225

*had
date*

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1998-866	19980520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Therkorn, Ernest G.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP, Fedrick, Michael F.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	203	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.